179 related articles for article (PubMed ID: 30068696)
21. Superior lentiviral vectors designed for BSL-0 environment abolish vector mobilization.
Hu P; Bi Y; Ma H; Suwanmanee T; Zeithaml B; Fry NJ; Kohn DB; Kafri T
Gene Ther; 2018 Oct; 25(7):454-472. PubMed ID: 30190607
[TBL] [Abstract][Full Text] [Related]
22. Design and in vitro characterization of a single regulatory module for efficient control of gene expression in both plasmid DNA and a self-inactivating lentiviral vector.
Ogueta SB; Yao F; Marasco WA
Mol Med; 2001 Aug; 7(8):569-79. PubMed ID: 11591893
[TBL] [Abstract][Full Text] [Related]
23. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.
Ni Y; Sun S; Oparaocha I; Humeau L; Davis B; Cohen R; Binder G; Chang YN; Slepushkin V; Dropulic B
J Gene Med; 2005 Jun; 7(6):818-34. PubMed ID: 15693055
[TBL] [Abstract][Full Text] [Related]
24. Sustained knockdown of a disease-causing gene in patient-specific induced pluripotent stem cells using lentiviral vector-based gene therapy.
Eggenschwiler R; Loya K; Wu G; Sharma AD; Sgodda M; Zychlinski D; Herr C; Steinemann D; Teckman J; Bals R; Ott M; Schambach A; Schöler HR; Cantz T
Stem Cells Transl Med; 2013 Sep; 2(9):641-54. PubMed ID: 23926210
[TBL] [Abstract][Full Text] [Related]
25. Lentiviral vector system for coordinated constitutive and drug controlled tetracycline-regulated gene co-expression.
Stahlhut M; Schwarzer A; Eder M; Yang M; Li Z; Morgan M; Schambach A; Kustikova OS
Biomaterials; 2015 Sep; 63():189-201. PubMed ID: 26113075
[TBL] [Abstract][Full Text] [Related]
26. Anti-HIV-1 gene expressing lentiviral vectors as an adjunctive therapy for HIV-1 infection.
Morris KV; Rossi JJ
Curr HIV Res; 2004 Apr; 2(2):185-91. PubMed ID: 15078182
[TBL] [Abstract][Full Text] [Related]
27. Development of a doxycycline-inducible lentiviral plasmid with an instant regulatory feature.
Yang T; Burrows C; Park JH
Plasmid; 2014 Mar; 72():29-35. PubMed ID: 24727543
[TBL] [Abstract][Full Text] [Related]
28. Eliminating HIV-1 Packaging Sequences from Lentiviral Vector Proviruses Enhances Safety and Expedites Gene Transfer for Gene Therapy.
Vink CA; Counsell JR; Perocheau DP; Karda R; Buckley SMK; Brugman MH; Galla M; Schambach A; McKay TR; Waddington SN; Howe SJ
Mol Ther; 2017 Aug; 25(8):1790-1804. PubMed ID: 28550974
[TBL] [Abstract][Full Text] [Related]
29. A lentiviral vector that activates latent human immunodeficiency virus-1 proviruses by the overexpression of tat and that kills the infected cells.
Macías D; Oya R; Saniger L; Martín F; Luque F
Hum Gene Ther; 2009 Nov; 20(11):1259-68. PubMed ID: 19604078
[TBL] [Abstract][Full Text] [Related]
30. Regulated delivery of glial cell line-derived neurotrophic factor into rat striatum, using a tetracycline-dependent lentiviral vector.
Georgievska B; Jakobsson J; Persson E; Ericson C; Kirik D; Lundberg C
Hum Gene Ther; 2004 Oct; 15(10):934-44. PubMed ID: 15585109
[TBL] [Abstract][Full Text] [Related]
31. Construction of a doxycycline inducible adipogenic lentiviral expression system.
Liu Q; Hill PJ; Karamitri A; Ryan KJ; Chen HY; Lomax MA
Plasmid; 2013 Jan; 69(1):96-103. PubMed ID: 23099229
[TBL] [Abstract][Full Text] [Related]
32. An improved Tet-On regulatable FasL-adenovirus vector system for lung cancer therapy.
Sipo I; Hurtado Picó A; Wang X; Eberle J; Petersen I; Weger S; Poller W; Fechner H
J Mol Med (Berl); 2006 Mar; 84(3):215-25. PubMed ID: 16437213
[TBL] [Abstract][Full Text] [Related]
33. Development of a liver-specific Tet-on inducible system for AAV vectors and its application in the treatment of liver cancer.
Vanrell L; Di Scala M; Blanco L; Otano I; Gil-Farina I; Baldim V; Paneda A; Berraondo P; Beattie SG; Chtarto A; Tenenbaum L; Prieto J; Gonzalez-Aseguinolaza G
Mol Ther; 2011 Jul; 19(7):1245-53. PubMed ID: 21364542
[TBL] [Abstract][Full Text] [Related]
34. Doxycycline regulated lentiviral vectors.
Markusic D; Seppen J
Methods Mol Biol; 2010; 614():69-76. PubMed ID: 20225036
[TBL] [Abstract][Full Text] [Related]
35. Lentivirus vector gene expression during ES cell-derived hematopoietic development in vitro.
Hamaguchi I; Woods NB; Panagopoulos I; Andersson E; Mikkola H; Fahlman C; Zufferey R; Carlsson L; Trono D; Karlsson S
J Virol; 2000 Nov; 74(22):10778-84. PubMed ID: 11044122
[TBL] [Abstract][Full Text] [Related]
36. Efficient in vivo regulation of cytidine deaminase expression in the haematopoietic system using a doxycycline-inducible lentiviral vector system.
Lachmann N; Brennig S; Pfaff N; Schermeier H; Dahlmann J; Phaltane R; Gruh I; Modlich U; Schambach A; Baum C; Moritz T
Gene Ther; 2013 Mar; 20(3):298-307. PubMed ID: 22592598
[TBL] [Abstract][Full Text] [Related]
37. Recent advances in lentiviral vector development and applications.
Mátrai J; Chuah MK; VandenDriessche T
Mol Ther; 2010 Mar; 18(3):477-90. PubMed ID: 20087315
[TBL] [Abstract][Full Text] [Related]
38. Transcriptional targeting of lentiviral vectors by long terminal repeat enhancer replacement.
Lotti F; Menguzzato E; Rossi C; Naldini L; Ailles L; Mavilio F; Ferrari G
J Virol; 2002 Apr; 76(8):3996-4007. PubMed ID: 11907239
[TBL] [Abstract][Full Text] [Related]
39. Strategies for targeting lentiviral vectors.
Frecha C; Szécsi J; Cosset FL; Verhoeyen E
Curr Gene Ther; 2008 Dec; 8(6):449-60. PubMed ID: 19075628
[TBL] [Abstract][Full Text] [Related]
40. Tetracycline-regulated gene expression in replication-incompetent herpes simplex virus vectors.
Schmeisser F; Donohue M; Weir JP
Hum Gene Ther; 2002 Dec; 13(18):2113-24. PubMed ID: 12542843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
